NEW YORK, NY / ACCESSWIRE / February 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Titan Pharmaceuticals, Inc. (TTNP) a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.
In this report a comprehensive pipeline review, update, progress and more READ REPORT
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/ttnp/
The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer.
An In-depth review of this lead product, company financials and full pipeline available here READ MORE
Copy and paste to your browser may be required to view the report- https://tradersnewssource.com/ttnp/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Traders News Source
View source version on accesswire.com: